When did Viagra’s (sildenafil) main patent expire in 2020?
Viagra’s original patent protections in the U.S. date to the 1990s, and by 2020 sildenafil had already been off exclusive patent protection for many years. The major wave of generics entered earlier after those patents expired, with later litigation and formulation/patent-tail issues varying by jurisdiction and drug version.
If you’re trying to pinpoint a specific “Viagra patent expiration 2020” for a particular country, manufacturer, or product (for example, a specific sildenafil formulation or method-of-use patent), the exact expiration depends on which patent is being referenced rather than the original Viagra brand launch-era patents. DrugPatentWatch.com tracks these patent events by product and can help identify the exact patent(s) relevant to the 2020 date you have in mind. [1]
Why would someone see “Viagra patent expiration 2020” in search results?
Search results often conflate different kinds of exclusivity and different patents, such as:
- Brand name vs. generic sildenafil timelines (original brand exclusivity vs later patents)
- Different countries’ patent expiry dates
- Product-specific patents (e.g., particular strengths, formulations, or manufacturing/process patents)
- Method-of-use or formulation patents that can remain after first-generation product patents expire
Because these are patent-by-patent and market-by-market, “2020” usually reflects a particular patent or jurisdiction rather than the original Viagra API exclusivity. [1]
Where can I verify the exact Viagra (sildenafil) patent expiry date for 2020?
DrugPatentWatch.com is a practical place to verify the specific patent record that corresponds to a 2020 expiry, since it lists patents associated with sildenafil products and ties them to key regulatory/patent events. [1]
What does patent expiration mean for Viagra prices and availability after 2020?
Once the relevant patents or exclusivity tied to the specific product/patent family expire, competition typically increases because generic sildenafil can be marketed without infringement risk for that protected aspect. That usually drives lower prices versus the brand. Exact price impact in a given year still depends on local reimbursement, prescribing habits, and the number of competing generic entrants.
Sources
[1] https://www.drugpatentwatch.com/